Ethnic disparities in breast tumor phenotypic subtypes in hispanic and non-hispanic white women

Journal of Women's Health

Volumn 20, Issue 10, 2011, Pages 1543-1550

  Hines, Lisa M ^a   Risendal, Betsy ^b   Byers, Tim ^b   Mengshol, Sarah ^c   Lowery, Jan ^b   Singh, Meenakshi ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b Food Science and Human Nutrition   (United States)

^c PRESBYTERIAN ST LUKE S MEDICAL CENTER   (United States)

^d STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CAUCASIAN; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; MIDDLE AGED; PHENOTYPE; REGISTRIES; SOUTHWESTERN UNITED STATES;

EID: 80054009382     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2010.2558     Document Type: Article

References (38)

1. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502. (Pubitemid 43854964)
2. Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptornegative, invasive breast cancer: The California Cancer Registry, 1999-2004. Cancer 2008;112:737-747. (Pubitemid 351240567)
3. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. Cancer 2007;109:1721-1728. (Pubitemid 46668532)
4. Stark A, Kleer CG, Martin I, et al. African ancestry and higher prevalence of triple-negative breast cancer: Findings from an international study. Cancer 2010;116:4926-4932.
5. Stead LA, Lash TL, Sobieraj JE, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 2009;11:R18.
6. Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 2009;15:593-602.
7. Lund MJ, Butler EN, Bumpers HL, et al. High prevalence of triple-negative tumors in an urban cancer center. Cancer 2008;113:608-615.
8. Lund MJ, Butler EN, Hair BY, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: A population-based study and first report. Cancer 2010;116:2549-2559.
9. Hsu JL, Glaser SL, West DW. Racial/ethnic differences in breast cancer survival among San Francisco Bay Area women. J Natl Cancer Inst 1997;89:1311-1312. (Pubitemid 27371952)
10. Boyer-Chammard A, Taylor TH, Anton-Culver H. Survival differences in breast cancer among racial/ethnic groups: A population-based study. Cancer Detect Prev 1999;23:463-473. (Pubitemid 29536877)
11. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 2003;163:49-56. (Pubitemid 36091600)
12. Clegg LX, Li FP, Hankey BF, et al. Cancer survival among US whites and minorities: A SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 2002;162:1985-1993.
13. Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 2003;97:134-147. (Pubitemid 36033873)
14. Frost F, Tollestrup K, Hunt WC, Gilliland F, Key CR, Urbina CE. Breast cancer survival among New Mexico Hispanic, American Indian, and non-Hispanic white women (1973- 1992). Cancer Epidemiol Biomarkers Prev 1996;5:861-866. (Pubitemid 26382978)
15. Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 2002;11:601-607. (Pubitemid 34760817)
16. Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 2001;92:37-45. (Pubitemid 32623038)
17. Chu KC, Anderson WF. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res Treat 2002;74:199-211. (Pubitemid 34848349)
18. Martinez ME, Nielson CM, Nagle R, Lopez AM, Kim C, Thompson P. Breast cancer among Hispanic and non- Hispanic white women in Arizona. J Health Care Poor Underserved 2007;18:130-145.
19. Hausauer AK, Keegan TH, Chang ET, Clarke CA. Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: Changes by tumor subtype. Breast Cancer Res 2007;9:R90.
20. Watlington AT, Byers T, Mouchawar J, Sauaia A, Ellis J. Does having insurance affect differences in clinical presentation between Hispanic and non-Hispanic white women with breast cancer? Cancer 2007;109:2093-2099. (Pubitemid 46744205)
21. Slattery ML, Sweeney C, Edwards S, et al. Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Res Treat 2007;102:85-101. (Pubitemid 46294955)
22. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43. (Pubitemid 46174133)
23. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010;134:e48- 72.
24. Tang P, Skinner KA, Hicks DG. Molecular classification of breast carcinomas by immunohistochemical analysis: Are we ready? Diagn Mol Pathol 2009;18:125-132.
25. Sweeney C, Baumgartner KB, Byers T, et al. Reproductive history in relation to breast cancer risk among Hispanic and non-Hispanic white women. Cancer Causes Control 2008;19: 391-401.
26. Hines LM, Risendal B, Slattery ML, Baumgartner KB, Giuliano AR, Byers T. Differences in estrogen receptor subtype according to family history of breast cancer among Hispanic, but not non-Hispanic white women. Cancer Epidemiol Biomarkers Prev 2008;17:2700-2706.
27. Hines LM, Risendal B, Slattery ML, et al. Comparative analysis of breast cancer risk factors among Hispanic and non-Hispanic white women. Cancer 2010;116:3215-3223.
28. Parise CA, Bauer KR, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol 2010;76:44-52.
29. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004;96:218-228. (Pubitemid 38263181)
30. Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast cancer risk factors defined by estrogen and progesterone receptor status: The multiethnic cohort study. Am J Epidemiol 2009;169:1251-1259.
31. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptordefined breast cancer: A systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004;13:1558-1568. (Pubitemid 39331875)
32. Kwan ML, Kushi LH, Weltzien E, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009;11:R31.
33. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: A prospective cohort of breast cancer patients. Breast Cancer Res 2007;9:R6.
34. Kurebayashi J, Moriya T, Ishida T, et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 2007;16 (Suppl 2):S72-77.
35. Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a populationbased study. Cancer Epidemiol Biomarkers Prev 2007;16: 439-443. (Pubitemid 46548646)
36. Lin CH, Liau JY, Lu YS, et al. Molecular subtypes of breast cancer emerging in young women in Taiwan: Evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev 2009;18:1807-1814.
37. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2/ neu-overexpressing phenotypes. Hum Pathol 2006;37:1217-1226. (Pubitemid 44286991)
38. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical end points. Am J Pathol 2001;159:2249-2256. (Pubitemid 33104278)